Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community o
How this was made
The 30-second read
Why it matters
The company posted a $3.4 M positive adjusted EBITDA and reaffirmed its 2026 revenue guidance of $650‑$660 M.
Market read
Earnings release provides fresh data for traders focused on healthcare micro‑caps.
What to watch
Potential headwinds from tariff and exchange‑rate pressures mentioned in the filing.
Background
Starling Oncology is a NASDAQ‑listed community oncology group that filed its Q3 2026 earnings via an SEC 8‑K.
Ticker impact
Starling Oncology reported Q3 2026 results with revenue up 24% YoY and reaffirmed full-year guidance.
likely modest upside as investors digest the reaffirmed guidance and improved EBITDA.
Positive revenue growth, positive adjusted EBITDA and no guidance updated suggest limited downside pressure.
Market effects
Strong specialty pharmacy growth may highlight opportunities in value‑based oncology services.
Results pertain to U.S. community oncology markets; limited broader regional effect.
Limited global impact; primarily a U.S. micro‑cap earnings story.
Counterpoint
If the market had priced in higher growth, reaffirmed guidance could be seen as a disappointment.
Key entities
- companyStarling Oncology, Inc.
NASDAQ‑listed oncology services provider.
